Lipocine (LPCN) Competitors

$2.21 -0.05 (-2.21%)

Closing price 05/18/2026 04:00 PM Eastern

Extended Trading

$2.20 0.00 (-0.23%)

As of 07:15 AM Eastern

LPCN vs. GANX, CLNN, XBIT, ICCC, and PMVP

Should you buy Lipocine stock or one of its competitors? MarketBeat compares Lipocine with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lipocine include Gain Therapeutics (GANX), Clene (CLNN), XBiotech (XBIT), ImmuCell (ICCC), and PMV Pharmaceuticals (PMVP). These companies are all part of the "pharmaceutical products" industry.

How does Lipocine compare to Gain Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

Gain Therapeutics has a beta of 0.15, meaning that its stock price is 85% less volatile than the broader market. Comparatively, Lipocine has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market.

Lipocine has higher revenue and earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50K	1,381.86	-$20.16M	-$0.58	N/A
Lipocine	$1.98M	9.20	-$9.63M	-$1.88	N/A

In the previous week, Lipocine had 3 more articles in the media than Gain Therapeutics. MarketBeat recorded 3 mentions for Lipocine and 0 mentions for Gain Therapeutics. Lipocine's average media sentiment score of 0.93 beat Gain Therapeutics' score of 0.87 indicating that Lipocine is being referred to more favorably in the news media.

Company	Overall Sentiment
Gain Therapeutics	Positive
Lipocine	Positive

Gain Therapeutics has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. Lipocine's return on equity of -66.70% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-201.44%	-136.24%
Lipocine	-571.18%	-66.70%	-59.39%

Gain Therapeutics presently has a consensus target price of $8.50, indicating a potential upside of 424.69%. Lipocine has a consensus target price of $15.00, indicating a potential upside of 578.73%. Given Lipocine's higher possible upside, analysts clearly believe Lipocine is more favorable than Gain Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 9.1% of Lipocine shares are held by institutional investors. 4.2% of Gain Therapeutics shares are held by company insiders. Comparatively, 6.4% of Lipocine shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Lipocine beats Gain Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Lipocine compare to Clene?

Clene (NASDAQ:CLNN) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

Clene presently has a consensus target price of $33.25, suggesting a potential upside of 389.69%. Lipocine has a consensus target price of $15.00, suggesting a potential upside of 578.73%. Given Lipocine's higher possible upside, analysts clearly believe Lipocine is more favorable than Clene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

In the previous week, Clene had 11 more articles in the media than Lipocine. MarketBeat recorded 14 mentions for Clene and 3 mentions for Lipocine. Lipocine's average media sentiment score of 0.93 beat Clene's score of 0.05 indicating that Lipocine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Clene	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lipocine	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lipocine has a net margin of -571.18% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clene	-25,009.70%	N/A	-137.98%
Lipocine	-571.18%	-66.70%	-59.39%

Clene has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market. Comparatively, Lipocine has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market.

23.3% of Clene shares are owned by institutional investors. Comparatively, 9.1% of Lipocine shares are owned by institutional investors. 28.3% of Clene shares are owned by insiders. Comparatively, 6.4% of Lipocine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Lipocine has higher revenue and earnings than Clene. Clene is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clene	$200K	433.88	-$26.17M	-$3.20	N/A
Lipocine	$1.98M	9.20	-$9.63M	-$1.88	N/A

Summary

Lipocine beats Clene on 9 of the 17 factors compared between the two stocks.

How does Lipocine compare to XBiotech?

Lipocine (NASDAQ:LPCN) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

9.1% of Lipocine shares are owned by institutional investors. Comparatively, 55.7% of XBiotech shares are owned by institutional investors. 6.4% of Lipocine shares are owned by company insiders. Comparatively, 30.8% of XBiotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Lipocine currently has a consensus price target of $15.00, indicating a potential upside of 578.73%. Given Lipocine's stronger consensus rating and higher possible upside, equities research analysts clearly believe Lipocine is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lipocine has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market. Comparatively, XBiotech has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market.

In the previous week, Lipocine had 1 more articles in the media than XBiotech. MarketBeat recorded 3 mentions for Lipocine and 2 mentions for XBiotech. Lipocine's average media sentiment score of 0.93 beat XBiotech's score of -0.26 indicating that Lipocine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lipocine	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
XBiotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lipocine has higher revenue and earnings than XBiotech. XBiotech is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipocine	$1.98M	9.20	-$9.63M	-$1.88	N/A
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A

XBiotech has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. XBiotech's return on equity of -26.10% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipocine	-571.18%	-66.70%	-59.39%
XBiotech	N/A	-26.10%	-25.06%

Summary

Lipocine beats XBiotech on 8 of the 15 factors compared between the two stocks.

How does Lipocine compare to ImmuCell?

Lipocine (NASDAQ:LPCN) and ImmuCell (NASDAQ:ICCC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment.

Lipocine currently has a consensus target price of $15.00, suggesting a potential upside of 578.73%. Given Lipocine's stronger consensus rating and higher probable upside, equities research analysts clearly believe Lipocine is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, ImmuCell had 2 more articles in the media than Lipocine. MarketBeat recorded 5 mentions for ImmuCell and 3 mentions for Lipocine. Lipocine's average media sentiment score of 0.93 beat ImmuCell's score of 0.81 indicating that Lipocine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lipocine	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmuCell	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ImmuCell has a net margin of -1.82% compared to Lipocine's net margin of -571.18%. ImmuCell's return on equity of -1.88% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipocine	-571.18%	-66.70%	-59.39%
ImmuCell	-1.82%	-1.88%	-1.22%

Lipocine has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market. Comparatively, ImmuCell has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market.

ImmuCell has higher revenue and earnings than Lipocine. ImmuCell is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipocine	$1.98M	9.20	-$9.63M	-$1.88	N/A
ImmuCell	$27.64M	3.24	-$1.04M	-$0.06	N/A

9.1% of Lipocine shares are owned by institutional investors. Comparatively, 13.5% of ImmuCell shares are owned by institutional investors. 6.4% of Lipocine shares are owned by company insiders. Comparatively, 5.7% of ImmuCell shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

ImmuCell beats Lipocine on 8 of the 15 factors compared between the two stocks.

How does Lipocine compare to PMV Pharmaceuticals?

Lipocine (NASDAQ:LPCN) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Lipocine has higher revenue and earnings than PMV Pharmaceuticals. Lipocine is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipocine	$1.98M	9.20	-$9.63M	-$1.88	N/A
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.49	N/A

PMV Pharmaceuticals has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. Lipocine's return on equity of -66.70% beat PMV Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipocine	-571.18%	-66.70%	-59.39%
PMV Pharmaceuticals	N/A	-68.98%	-62.70%

9.1% of Lipocine shares are held by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are held by institutional investors. 6.4% of Lipocine shares are held by insiders. Comparatively, 7.6% of PMV Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Lipocine has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market. Comparatively, PMV Pharmaceuticals has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market.

Lipocine presently has a consensus price target of $15.00, indicating a potential upside of 578.73%. PMV Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 300.00%. Given Lipocine's higher possible upside, equities analysts plainly believe Lipocine is more favorable than PMV Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Lipocine had 2 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 3 mentions for Lipocine and 1 mentions for PMV Pharmaceuticals. PMV Pharmaceuticals' average media sentiment score of 2.44 beat Lipocine's score of 0.93 indicating that PMV Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Lipocine	Positive
PMV Pharmaceuticals	Very Positive

Summary

PMV Pharmaceuticals beats Lipocine on 9 of the 15 factors compared between the two stocks.

Get Lipocine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LPCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LPCN vs. The Competition

Export

Metric	Lipocine	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$18.63M	$3.00B	$6.25B	$12.29B
Dividend Yield	N/A	1.98%	2.80%	5.32%
P/E Ratio	-1.18	17.22	20.64	25.23
Price / Sales	9.20	286.32	554.85	79.36
Price / Cash	N/A	56.35	27.48	37.30
Price / Book	0.85	3.93	9.66	6.63
Net Income	-$9.63M	$74.99M	$3.56B	$335.59M
7 Day Performance	-5.15%	-4.47%	-1.65%	-1.20%
1 Month Performance	-9.05%	-7.93%	-2.60%	-1.16%
1 Year Performance	-39.12%	29.34%	30.07%	28.10%

Lipocine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LPCN Lipocine	3.7146 of 5 stars	$2.21 -2.2%	$15.00 +578.7%	-44.6%	$18.63M	$1.98M	N/A	10	News Coverage
GANX Gain Therapeutics	1.7738 of 5 stars	$1.80 -1.1%	$8.50 +372.2%	-19.4%	$76.78M	N/A	N/A	20
CLNN Clene	3.2256 of 5 stars	$6.50 flat	$33.25 +411.5%	+164.2%	$76.56M	$200K	N/A	100	Earnings Report
XBIT XBiotech	0.3247 of 5 stars	$2.50 +1.2%	N/A	-21.1%	$76.23M	N/A	N/A	100	Earnings Report Gap Up
ICCC ImmuCell	0.9834 of 5 stars	$8.38 -0.8%	N/A	+88.0%	$75.84M	$27.64M	N/A	70	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LPCN) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lipocine (LPCN) Competitors

LPCN vs. GANX, CLNN, XBIT, ICCC, and PMVP

How does Lipocine compare to Gain Therapeutics?

Summary

How does Lipocine compare to Clene?

Summary

How does Lipocine compare to XBiotech?

Summary

How does Lipocine compare to ImmuCell?

Summary

How does Lipocine compare to PMV Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LPCN vs. The Competition

Lipocine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lipocine (LPCN) Competitors

LPCN vs. GANX, CLNN, XBIT, ICCC, and PMVP

How does Lipocine compare to Gain Therapeutics?

Which has more risk and volatility, GANX or LPCN?

Which has stronger valuation and earnings, GANX or LPCN?

Does the media favor GANX or LPCN?

Is GANX or LPCN more profitable?

Do analysts prefer GANX or LPCN?

Do insiders & institutionals hold more shares of GANX or LPCN?

Summary

How does Lipocine compare to Clene?

Do analysts rate CLNN or LPCN?

Does the media prefer CLNN or LPCN?

Is CLNN or LPCN more profitable?

Which has more risk & volatility, CLNN or LPCN?

Do insiders and institutionals hold more shares of CLNN or LPCN?

Which has stronger valuation and earnings, CLNN or LPCN?

Summary

How does Lipocine compare to XBiotech?

Do institutionals & insiders have more ownership in LPCN or XBIT?

Do analysts prefer LPCN or XBIT?

Which has more risk and volatility, LPCN or XBIT?

Does the media favor LPCN or XBIT?

Which has better valuation and earnings, LPCN or XBIT?

Is LPCN or XBIT more profitable?

Summary

How does Lipocine compare to ImmuCell?

Do analysts rate LPCN or ICCC?

Does the media favor LPCN or ICCC?

Is LPCN or ICCC more profitable?

Which has more volatility & risk, LPCN or ICCC?

Which has preferable valuation & earnings, LPCN or ICCC?

Do institutionals & insiders hold more shares of LPCN or ICCC?

Summary

How does Lipocine compare to PMV Pharmaceuticals?

Which has better earnings and valuation, LPCN or PMVP?

Is LPCN or PMVP more profitable?

Do insiders and institutionals believe in LPCN or PMVP?

Which has more risk and volatility, LPCN or PMVP?

Do analysts recommend LPCN or PMVP?

Does the media favor LPCN or PMVP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LPCN vs. The Competition

Lipocine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools